{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:32:28Z","timestamp":1789842748334,"version":"4.0.1"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18\u00a0F]-FDG PET\/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18\u00a0F]-FDG PET\/CT scans in patients treated with capivasertib.<\/jats:p>","DOI":"10.1186\/s41824-024-00231-7","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T23:04:06Z","timestamp":1742771046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Capivasertib treatment associated with hypermetabolism of the spleen"],"prefix":"10.1186","volume":"9","author":[{"given":"Maria","family":"Ly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary Z.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8263-903X","authenticated-orcid":false,"given":"Amin Haghighat","family":"Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"231_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","volume":"63","author":"A Andrikopoulou","year":"2022","unstructured":"Andrikopoulou A, Chatzinikolaou S, Panourgias E et al (2022) The emerging role of capivasertib in breast cancer. Breast 63:157\u2013167","journal-title":"Breast"},{"key":"231_CR2","doi-asserted-by":"crossref","unstructured":"Luboff AJ, DeRemer DL, Capivasertib (2024) A novel AKT inhibitor approved for hormone-Receptor-Positive, HER-2-Negative metastatic breast Cancer. Ann Pharmacother.:10600280241241531","DOI":"10.1177\/10600280241241531"},{"key":"231_CR3","doi-asserted-by":"crossref","unstructured":"Rugo HS, Oliveira M, Howell SJ et al (2023) Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+\/HER2\u2013advanced breast cancer (ABC): characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2023.41.16_suppl.1067"},{"key":"231_CR4","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ et al (2023) Capivasertib in hormone receptor-positive advanced breast Cancer. N Engl J Med 388:2058\u20132070","journal-title":"N Engl J Med"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-024-00231-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00231-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T23:04:09Z","timestamp":1742771049000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-024-00231-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":4,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["231"],"URL":"https:\/\/doi.org\/10.1186\/s41824-024-00231-7","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the nature of the retrospective study involving anonymized cases, need for ethics approval was waived. Consent was obtained from patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare that they have no financial disclosures or conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}